Qushi Juanbi Granules Combined with Shenling Baizhu Powder in Rheumatoid Arthritis Patients with Low Disease Activity and Pi Deficiency and Dampness Pattern: A Randomized, Double-Blind, Controlled Trial.
Chin J Integr MedJul 28, 2026 (epub)
Yi-Hong Yang, Kai-Xin Gao, You-Bang Liang et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, controlled trial evaluated the efficacy and safety of Qushi Juanbi Granules (QSJB) combined with Shenling Baizhu Powder (SLBZ) in 60 rheumatoid arthritis patients with low disease activity and Pi deficiency. While both treatments improved disease activity, the QSJB+SLBZ group showed faster relief of joint pain, with significant improvements in tender and swollen joint counts after 4 weeks (P=0.002 and P=0.001, respectively).
Key findings
- In the QSJB+SLBZ group, TJC28 improved significantly after 4 weeks (P=0.029).
- DAS28-CRP improved in the QSJB group after 12 weeks (P=0.024).
- No significant differences in overall adverse events between groups (all P>0.05).
- Week-12 remission rate was numerically higher in the QSJB+SLBZ group (P=0.745).
Why it matters
The findings suggest that combining QSJB with SLBZ may enhance the management of rheumatoid arthritis by providing quicker relief of joint pain, which is crucial for improving patient quality of life.